Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P Cahn, J Andrade-Villanueva, JR Arribas… - The Lancet Infectious …, 2014 - thelancet.com
Background Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P Cahn, J Andrade-Villanueva, JR Arribas… - The Lancet Infectious …, 2014 - Elsevier
Background Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P Cahn, J Andrade-Villanueva, JR Arribas, JM Gatell… - 2014 - cabidigitallibrary.org
Background: Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P Cahn, J Andrade-Villanueva, JR Arribas… - The Lancet. Infectious …, 2014 - europepmc.org
Background Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P Cahn, J Andrade-Villanueva, JR Arribas… - The Lancet Infectious …, 2014 - infona.pl
Daily oral triple therapy is effective at halting HIV disease progression, but can have toxic
effects and is costly. We investigated whether dual therapy with lopinavir and ritonavir plus …
effects and is costly. We investigated whether dual therapy with lopinavir and ritonavir plus …
[引用][C] Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P CAHN, J ANDRADE-VILLANUEVA… - Lancet. Infectious …, 2014 - pascal-francis.inist.fr
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir
and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive …
and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive …
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P Cahn, J Andrade-Villanueva, JR Arribas… - Lancet Infect …, 2014 - thelancet.com
Background Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
[PDF][PDF] Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P Cahn, J Andrade-Villanueva, JR Arribas… - Lancet Infect …, 2014 - corevih-bretagne.fr
Background Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P Cahn, J Andrade-Villanueva… - The Lancet …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Daily oral triple therapy is effective at halting HIV disease progression, but can
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …
have toxic effects and is costly. We investigated whether dual therapy with lopinavir and …